Your Yourlocation: Home > Effect of azithromycin combined with tiotropium bromide(136310-93-5) on bronchiectasis

OBJECTIVE: To observe the efficacy of long-term low-dose oral azithromycin combined with tiotropium bromide(136310-93-5) in the stable phase of bronchiectasis.

Methods: 90 patients with bronchodilator were divided into treatment group (n = 70) and control group (n = 20). The control group was treated with conventional expectorant therapy. The treatment group was divided into group A (azithromycin combined thiophene (N = 20), group B (tiotropium bromide) and group C (azithromycin) were treated with the above-mentioned drugs for 6 months. The lung function was observed before and after treatment in each group. Protein(hs-CRP), sputum daily and sputum bacterial culture positive rate and acute exacerbations.

Results: Compared with the control group, the above four indexes were significantly improved (P <0.01). The pulmonary function of group B was significantly improved, the number of acute exacerbations and the amount of sputum per day were significantly decreased (P <0.05). The number of hs-CRP in group C was decreased, the sputum volume was decreased, the positive rate of sputum culture and the number of acute attack were decreased, and the lung function was significantly improved (P <0.05).

Conclusion: Long - term low - dose oral administration of azithromycin combined with tiotropium bromide(136310-93-5) can improve the pulmonary function of patients with bronchodilator, reduce the inflammatory index, reduce the clinical symptoms and reduce the number of acute exacerbations.

Address: TEL:0531-82375879 Tiotropium Bromide
© Copyright(C)2014 JINAN DEXINJIA BIO & TECH CO., LTD All Rights Reserved